As GBMs are characterized by high heterogeneity and massive vessels, anti‐VEGF therapy was expected to improve the outcome of GBM patients.27 Bevacizumab, a humanized monoclonal antibody against VEGF, has been the most promising anti‐angiogenic agents for treating GBMs and was approved for recurrent GBM treatment.28 However, in newly diagnosed GBM patients, recent randomized trials failed to yield clear survival benefits when applied bevacizumab plus Stupp regimen,29 implying that proper indicators are needed for bevacizumab treatment. The gene discussed is VEGFA; the disease is glioblastoma.